Cellectar Biosciences (Formerly Known As Novelos Therapeutics, Inc.)
3301 Agriculture Drive
256 articles with Cellectar Biosciences (Formerly Known As Novelos Therapeutics, Inc.)
A roundup of last week's top clinical trial updates and news.
Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.
BioSpace Movers & Shakers, Feb. 25
2/25/2022Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Clinical Catch-Up: December 11-17
12/20/2021It was an enormously busy week with plenty of announcements from the American Society of Hematology meeting and numerous companies working to get the news out ahead of the holidays and year-end. Here’s a look.
Clinical Catch-Up: November 15-19
11/22/2021With the last full week before the Thanksgiving week in the U.S., companies had a fair amount of clinical trial news. Here’s a look.
Clinical Catch-Up: September 20-24
9/27/2021There was still some carryover from the European Society of Medical Oncology Congress 2021, but there was plenty of other clinical trial news last week. Here’s a look.
Clinical Catch-Up: February 17-21
2/24/2020Mid-February had a solid number of clinical trial announcements. Here’s a look.
Clinical Catch-Up: December 16-20
12/23/2019Heading into the holidays, there was still plenty of clinical trial news last week. Here’s a look.
Clinical Catch-Up: December 9-13
12/16/2019It was a particularly busy week in clinical trial news, largely because of the American Society of Hematology Annual Meeting. Here’s a look.
As the 61st American Society of Hematology Annual Meeting wrapped up in Orlando, Florida, there were hundreds of studies and results presented. Here’s a look at some.
It was another busy week for clinical trials. Here’s a look.
Clinical Catch-Up: September 16-20
9/23/2019Last week was an unusually busy week for clinical trial news, with numerous companies presenting results at conferences. Here’s a look at the top stories.
Cellectar Receives FDA Fast Track Designation for CLR 131 in Diffuse Large B-Cell Lymphoma
Cellectar Biosciences, Inc. announced the U.S. Food and Drug Administration has granted Fast Track Designation for CLR 131 in relapsed or refractory Diffuse Large B-Cell Lymphoma.
Cellectar Initiates DLBCL Cohort in Phase II Trial of CLR 131 in Refractory B-Cell Hematologic Cancers
The Company expects to enroll up to 10 patients with DLBCL into this cohort prior to conducting an interim analysis.
Cellectar Biosciences is closing its manufacturing operations and contracting them out.
Cellectar Files IND for Phase I Trial of CLR 131 in Pediatric Cancers
The study will be initiated with the pediatric oncologists and Nuclear Medicine/Radiology Group at The University of Wisconsin Carbone Cancer Center.
Cellectar Announces Expansion of Relapsed/Refractory Multiple Myeloma Cohort in Phase II Trial of CLR 131
Multiple myeloma cohort exceeded pre-specified criteria for clinically meaningful benefit.
Cellectar Biosciences Reports Third Quarter 2017 Financial and Corporate Performance
Cash and cash equivalents as of September 30, 2017 were approximately $5.7 million compared to approximately $11.4 million as of December 31, 2016.
Cellectar Announces Updated Median Overall Survival of 26.2 Months from Cohort 1 of CLR 131 Phase I Trial in Advanced Multiple Myeloma
While no head-to-head studies have been conducted for comparison, the median overall survival benefit seen with the three most recently FDA-approved third line therapies for multiple myeloma ranges from 11.9 – 18.6 months in separate trials.
Cellectar Biosciences to Host Conference Call on November 10, 2017 to Report Third Quarter 2017 Financial Results and Corporate Performance
The live and archived webcast can be accessed via the company’s website